CLIMB BIO, INC. Other Comprehensive Income (Loss), Net of Tax
CLIMB BIO, INC. (CLYM) reported Other Comprehensive Income (Loss), Net of Tax of $263.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2025-05-14
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-03-31 was $263.00K, a 13050.00% increase year-over-year.
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $201.00K, a 737.50% increase year-over-year.
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was $2.00K, a 99.24% decline year-over-year.
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $24.00K, a 4.35% increase year-over-year.
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for fiscal 2024 was $25.00K, a 92.98% decline from fiscal 2023.
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $356.00K.
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$235.00K.
- CLIMB BIO, INC. other comprehensive income (loss), net of tax for fiscal 2021 was -$123.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2025-03-31 | $263.00K 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $25.00K 10-K · filed 2025-03-25 | |||
| 2024-09-30 | $201.00K 10-Q · filed 2024-11-12 | |||
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $356.00K 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $24.00K 10-Q · filed 2024-11-12 | $84.00K derived: sum of 2 quarters · filed 2024-11-12 | $347.00K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $60.00K 10-Q · filed 2024-11-12 | $323.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $263.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | -$235.00K 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $23.00K 10-Q · filed 2023-11-14 | -$60.00K derived: sum of 2 quarters · filed 2023-11-14 | -$458.00K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$83.00K 10-Q · filed 2023-11-14 | -$481.00K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | -$398.00K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | -$123.00K 10-K · filed 2023-03-06 | |||
| 2021-09-30 | -$18.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |